Literature DB >> 108204

Staphylococcus aureus opsonization mediated via the classical and alternative complement pathways. A kinetic study using MgEGTA chelated serum and human sera deficient in IgG and complement factors C1s and C2.

H A Verbrugh, W C Van Dijk, R Peters, M E Van Der Tol, P K Peterson, J Verhoef.   

Abstract

Staphylococcus aureus opsonization was studied kinetically by: (1) determination of the uptake of [3H]-thymidine labelled bacteria by human PMN's; (2) fluorescent anti-C3 and anti-IgG staining of opsonized bacteria; and (3) measuring bacterial complement consumption. Maximum opsonization in normal serum occurred within 5 min of incubation. About 80% of staphylococci were then taken up by PMN's, and IgG and C3b could be detected on the bacterial surface. In the absence of a functional classical complement pathway, as in sera deficient in C1s and C2 and in MgEGTA chelated serum, maximal opsonization was only achieved after 30--60 min incubation. Opsonization in IgG deficient serum occurred at a rate similar to that found in C2 deficient or MgEGTA chelated serum. Opsonization was greatly enhanced when sera were reconstituted. It was concluded that in IgG deficient serum Staphylococcus aureus opsonization is mediated via the alternative complement pathway. Dilution of normal serum primarily affected the classical complement pathway, resulting in a decreased rate of opsonization. In normal serum IgG did not appear to be a rate-limiting factor. S. Aureus opsonization was best studied by the phagocytosis assay and the fluorescent-antibody technique. Measuring haemolytic complement consumption was found to be an insensitive indicator of bacterial complement activation and opsonization.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 108204      PMCID: PMC1457553     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  17 in total

Review 1.  Phagocytosis: recognition and ingestion.

Authors:  T P Stossel
Journal:  Semin Hematol       Date:  1975-01       Impact factor: 3.851

2.  Opsonic requirements for phagocytosis of Streptococcus pneumoniae types VI, XVIII, XXIII, and XXV.

Authors:  G S Giebink; J Verhoef; P K Peterson; P G Quie
Journal:  Infect Immun       Date:  1977-11       Impact factor: 3.441

3.  Opsonic activity in human serum deficient in C2.

Authors:  F R Johnson; V Agnello; R C Williams
Journal:  J Immunol       Date:  1972-07       Impact factor: 5.422

4.  Staphylococcal heat-stable opsonins.

Authors:  D W Humphreys; L J Wheat; A White
Journal:  J Lab Clin Med       Date:  1974-07

5.  Opsonic requirements for staphylococcal phagocytosis. Heterogeneity among strains.

Authors:  J Verhoef; P Peterson; Y Kim; L D Sabath; P G Quie
Journal:  Immunology       Date:  1977-08       Impact factor: 7.397

6.  Human heat labile opsonins: evidence for their mediation via the alternate pathway of complement activation.

Authors:  H E Jasin
Journal:  J Immunol       Date:  1972-07       Impact factor: 5.422

7.  Leukocytic function in hypogammaglobulinemia.

Authors:  I D Mickenberg; R K Root; S M Wolff
Journal:  J Clin Invest       Date:  1970-08       Impact factor: 14.808

8.  Activation of complement by opportunist pathogens and chemotypes of Salmonella minnesota.

Authors:  A B Bjornson; H S Bjornson
Journal:  Infect Immun       Date:  1977-06       Impact factor: 3.441

9.  Influence of the alternate complement pathway in opsonization of several bacterial species.

Authors:  A Forsgren; P G Quie
Journal:  Infect Immun       Date:  1974-08       Impact factor: 3.441

10.  The opsonic fragment of the third component of human complement (C3).

Authors:  T P Stossel; R J Field; J D Gitlin; C A Alper; F S Rosen
Journal:  J Exp Med       Date:  1975-06-01       Impact factor: 14.307

View more
  14 in total

1.  Quantitation of the third component of human complement attached to the surface of opsonized bacteria: opsonin-deficient sera and phagocytosis-resistant strains.

Authors:  H A Verbrugh; W C van Dijk; M E van Erne; R Peters; P K Peterson; J Verhoef
Journal:  Infect Immun       Date:  1979-12       Impact factor: 3.441

2.  Opsonization and phagocytosis of mucoid and non-mucoid Pseudomonas aeruginosa strains.

Authors:  T Meshulam; H A Verbrugh; J Verhoef
Journal:  Eur J Clin Microbiol       Date:  1982-04       Impact factor: 3.267

3.  Antibody-independent classical pathway-mediated opsonophagocytosis of type Ia, group B streptococcus.

Authors:  C J Baker; M S Edwards; B J Webb; D L Kasper
Journal:  J Clin Invest       Date:  1982-02       Impact factor: 14.808

4.  Influence of serum concentration on opsonization by the classical and alternative complement pathways.

Authors:  R W Tofte; P K Peterson; Y Kim; P G Quie
Journal:  Infect Immun       Date:  1980-02       Impact factor: 3.441

5.  The role of Staphylococcus aureus cell-wall peptidoglycan, teichoic acid and protein A in the processes of complement activation and opsonization.

Authors:  H A Verbrugh; W C Van Dijk; R Peters; M E Van Der Tol; J Verhoef
Journal:  Immunology       Date:  1979-07       Impact factor: 7.397

6.  Phagocytosis and killing of Staphylococcus aureus by human neutrophils.

Authors:  Thea Lu; Adeline R Porter; Adam D Kennedy; Scott D Kobayashi; Frank R DeLeo
Journal:  J Innate Immun       Date:  2014-04-05       Impact factor: 7.349

7.  Phagocytosis of staphylococci by human polymorphonuclear leukocytes is enhanced in the presence of endothelial cells.

Authors:  C M Vandenbroucke-Grauls; H M Thijssen; J Verhoef
Journal:  Infect Immun       Date:  1985-10       Impact factor: 3.441

8.  Interaction between human polymorphonuclear leucocytes and Staphylococcus aureus in the presence and absence of opsonins.

Authors:  C M Vandenbroucke-Grauls; H M Thijssen; J Verhoef
Journal:  Immunology       Date:  1984-07       Impact factor: 7.397

9.  Chemiluminescent response to pathogenic organisms: normal human polymorphonuclear leukocytes.

Authors:  P Robinson; D Wakefield; S N Breit; J F Easter; R Penny
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

10.  Complement consumption gonococcal peptidoglycan.

Authors:  B H Petersen; R S Rosenthal
Journal:  Infect Immun       Date:  1982-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.